NCT00240552CompletedPhase 4
An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- ViiV Healthcare
- Enrollment
- 85
- Locations
- 12
Study Overview
Brief Summary
This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •HIV-1 infected subjects.
- •Subjects must belong to one of the following populations:
- •Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
- •Subjects who already receive amprenavir (Agenerase®)
- •Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.
Exclusion Criteria
- Not provided
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Completed
Not Applicable
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.HIV InfectionsNCT00002173The Immune Response Corporation
Available
Not Applicable
Expanded Access to TriheptanoinLong Chain Fatty Acid Oxidation DisordersNCT03773770Ultragenyx Pharmaceutical Inc
Completed
Phase 2
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected PatientsHIV InfectionsNCT00002234Gilead Sciences25
Completed
Phase 3
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral TherapyHIV InfectionsNCT00004978National Institute of Allergy and Infectious Diseases (NIAID)4,150
Active, not recruiting
Phase 4
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCNon-squamous NSCLCNCT04413201Michael Hopp34